12:00 AM
 | 
Sep 10, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor coactivator 1 (NCOA1; SRC1); NCOA2 (SRC2); NCOA3 (SRC3; AIB1)

Cancer

INDICATION: Cancer

In vitro and mouse studies suggest co-stimulating NCOA1, NCOA2 and NCOA3 could help treat cancer. In multiple human cancer cell lines, a small molecule research compound that...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >